Technical Requirements for Pharmaceuticals. Experience with submissions of dossiers

Similar documents
Scientific Discussion post-authorisation update for Rheumocam extension X/007

Guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Public Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC

Scientific discussion

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound

SCIENTIFIC DISCUSSION

Dosing Your Cat with Azithromycin Pediatric Suspension. By Lorraine Shelton

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

Illegal veterinary drugs. How to ensure the quality and traceability of Veterinary Medicinal Products

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

PROFESSIONAL PRACTICE STANDARD

VETERINARY PRODUCT REGISTRATION

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

GUIDELINES ON LABELLING OF STOCK REMEDIES IN SOUTH AFRICA. Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Panel Discussion: Industry Perspective on PET Drug Manufacturing

AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Administering wormers (anthelmintics) effectively

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

GUIDELINE ON LABELLING OF STOCK REMEDIES

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

LABELLING AND PACKAGE LEAFLET

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP Adopted 2005

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

I.3. Central competent authority. Local competent authority I.6. I.12. I.16. Entry BIP in EU. I.17. No(s) of CITES. I.22. Number of packages

Paul-Ehrlich-Institut Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Federal Institute for Vaccines and Biomedicines

ANNEXES. to the Proposal. for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

Public Assessment Report Scientific discussion

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

CMD(v) ANNOTATED QRD TEMPLATE. MRP/DCP adapted version based on version 7 of 8/2005

ESTONIAN STATE AGENCY OF MEDICINES LATVIAN FOOD AND VETERINARY SERVICE LITHUANIAN NATIONAL FOOD AND VETERINARY RISK ASSESSMENT INSTITUTE

Recognition of Export Controls and Certification Systems for Animals and Animal Products. Guidance for Competent Authorities of Exporting Countries

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France

Review of Legislation for Veterinary Medicinal Products Version 2

Snapshot Current Vet Drugs AMR Initiatives

Tamboli Ashpak Mubarak et al. IRJP 2 (8)

Public Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)

Guidance Document. Pig Semen PIGSEMEN.GEN. [Document Date] A guidance document issued by the Ministry for Primary Industries

Import Health Standard

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

IMPORT HEALTH STANDARD FOR THE IMPORTATION INTO NEW ZEALAND OF RABBIT MEAT FOR HUMAN CONSUMPTION FROM THE EUROPEAN COMMUNITY

[Version 8.1, 01/2017]

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE

Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial Animal Health

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

Review of requirements and processes for registration of veterinary products in selected African and Asian countries

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

LABELLING AND PACKAGE LEAFLET A. LABELLING

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

They're not all the same: Why FDA approval of animal drugs matters

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Republic of the Philippines Ministry of Health OFFICE OF THE SECRETARY Manila REQUIREMENT FOR LABELLING MATERIALS OF VETERINARY DRUGS AND PRODUCTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Moxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

EXCEDE Sterile Suspension

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

A Guide to Veterinary Authorising (Prescribing) and Dispensing

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

ruma Cattle Responsible use of antimicrobials in Cattle production GUIDELINES

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

Summary of product characteristics As per Annex C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1

drugs, which examine by central competent authorities.

The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial & Aquatic Animals

National experience of application of the requirements for marketing authorisations and other ways of making vaccines available - small MS perspective

MARKET SURVEY CONCERNING ORGANIZATIONAL CONDITIONS OF VETERINARY PHARMACIES IN BUCHAREST

THE ADVANTAGES OF cgmp Manufactured Veterinary Drugs

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Central competent authority. Local competent authority. I.16. Entry BIP in EU. I.17. No.(s) of CITES

SUMMARY of PRODUCT CHARACTERISTICS

THE IMPORTANCE OF QUALITY IN COMPOUNDED VETERINARY MEDICINES

LIFE.2.B EUROPEAN UNION. Brussels, 14 November 2018 (OR. en) 2014/0255 (COD) PE-CONS 43/18 AGRILEG 102 VETER 52 CODEC 1149

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Company: Richter Pharma AG MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Guidance Document. Hides and Skins HIDESKIN.ALL. 7 August A guidance document issued by the Ministry for Primary Industries

Summary of Product Characteristics

Transcription:

Technical Requirements for Pharmaceuticals. Experience with submissions of dossiers Henrik K.Nielsen Technical Specialist Essential Medicines Unit - Medicines and Nutrition Centre UNICEF SUPPLIER MEETING 27-28 SEPTEMBER 2010 UNICEF SUPPLY DIVISION - COPENHAGEN, DENMARK

UNICEF SD Product evaluation is a key tool to ensure product quality UNICEF SD Technical Requirements for Pharmaceutical products The Interagency Pharmaceutical Product questionnaire

UNICEF SD UNICEF SD Technical Requirements for Pharmaceutical products Accompanies every tender for pharmaceutical products http://www.unicef.org/supply/files/unicef_tech nical_requirements_for_pharmaceutical_produc ts_-_3rd_edition_-_april_2010.pdf

UNICEF SD

Specifications Specifications are reviewed and if necessary updated in connection with every Tender. Eg Nystatin oral suspension General Description: Nystatin oral suspension 100 000 IU/ml, bottle of 30 ml. Technical Specifications: The oral suspension should contain 100 000 IU/ml Nystatin complying with one of the pharmacopeias: BP Ph. Eur Ph. Int USP

Specifications Nystatin oral suspension, continued The oral suspension should comply with one of the pharmacopeias: Nystatin Oral Suspension BP, general monograph for oral liquids and general notices Ph.Eur. general monograph for liquids preparations for oral use and general notices Ph.Int. general monograph for liquid preparations for oral use and general notices Nystatin Oral Suspension USP and general notices and requirements

Specifications Packaging and Labelling: As per UNICEF Technical Requirements. Each dose is to be administered by means of a device suitable for measuring the prescribed volume (usually a syringe graduated by the measurement of 0.1ml). The measuring device should be enclosed with or attached to each bottle.

Technical Requirements for Pharmaceutical products Complete Pharmaceutical Questionnaire for Manufacturers Complete Interagency Agency Pharmaceutical Questionnaire Full International Non-proprietary Name (INN name)/no brand or trade name WHO-GMP Certificate Manufacturing license in country of origin Marketing Authorisation in country of origin, and exporting countries if applicable Certificate of Pharmaceutical Product (CPP) API, References to Pharmacopeias and CEP/DMF

Technical Requirements for Pharmaceutical products Specifications for Finished Pharmaceutical Products (reference: International Pharmacopeia, European Pharmacopeia/British Pharmacopeia or United States Pharmacopeia) and monographs where applicable CoA s of 3 production batches Stability studies of the Finished Pharmaceutical Product Language requirements: English and French unless other specified Expiry date format: dd/mm/yyyy

UNICEF SD The Interagency Pharmaceutical Product questionnaire

Interagency Pharmaceutical Product questionnaire Standardised technical evaluations of pharmaceutical products Reduced workload for both the bidder and agencies Considered as the basic minimum Currently part of the WHO Model QA system for procurement agencies

Challenges: Incomplete filled in questionnaire Inadequate information In general follow up via e-mails

Challenges: Notification about changes: Finished product specifications Container closure systems Stability testing methodologies, API source, routes of synthesis and/or specifications of API, GMP status, manufacturing processes, contract manufacture if any and manufacturing site.

Challenges, Experiences: Samples (Fit-for-purpose/usability) e.g.: Appropriate sealing of primary container. Large Volume Parenterals w.giving set Injectables together w. specific diluents Number of samples and in case of changes resubmission of new samples Break marks solid tablets Oral liquids with dose measuring devices

Challenges: Many companies include the Essential Medicines logo in the packaging materials. Please note the logo is a property of WHO.

Challenges: Stability studies should be conducted in the final packaging reflecting real time and accelerated stability studies as per WHO/ICH Guidelines In stability report numerical results should be stated instead of conforms/complies The proposed shelf-life must be supported by the stability studies submitted Storage conditions should be based on and reflect stability studies

Challenges: Example: Store in a cool place protected from light Do not store above 25 C protected from light PLEASE for the future Perform stability realtime studies Zone IV a 30 C/ 65 RH Zone IV b 30 C/ 75 RH

Thank You